{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/KPTI/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-09-29T15:32:06.130Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":3001,"canonical_name":"Karyopharm Therapeutics Inc.","cik":"0001503802","uei":null,"lei":null,"duns":null,"ticker":"KPTI"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":34},"count":34,"timeline":[{"ts":"2026-08-11","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Karyopharm Therapeutics Inc. — 2026-08-11","url_slug":"/sec/cik-0001503802/schedule-13g-a/0000886982-26-000401","accession_number":"0000886982-26-000401","importance":30},{"ts":"2026-07-17","kind":"sec.filing","form_type":"8-K","title":"8-K — Karyopharm Therapeutics Inc. — 2026-07-17","url_slug":"/sec/cik-0001503802/8-k/0001193125-26-307964","accession_number":"0001193125-26-307964","importance":35},{"ts":"2026-06-05","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Karyopharm Therapeutics Inc. — 2026-06-05","url_slug":"/sec/cik-0001503802/schedule-13g-a/0001897612-26-000511","accession_number":"0001897612-26-000511","importance":30},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Karyopharm Therapeutics Inc. — 2026-05-15","url_slug":"/sec/cik-0001503802/schedule-13g/0001193125-26-227136","accession_number":"0001193125-26-227136","importance":55},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Karyopharm Therapeutics Inc. — 2026-05-15","url_slug":"/sec/cik-0001503802/schedule-13g/0001636587-26-000031","accession_number":"0001636587-26-000031","importance":55},{"ts":"2026-05-15","kind":"sec.filing","form_type":"4","title":"4 — Karyopharm Therapeutics Inc. — 2026-05-15","url_slug":"/sec/cik-0001503802/4/0001193125-26-226604","accession_number":"0001193125-26-226604","importance":30},{"ts":"2026-05-15","kind":"sec.filing","form_type":"4","title":"4 — Karyopharm Therapeutics Inc. — 2026-05-15","url_slug":"/sec/cik-0001503802/4/0001193125-26-226613","accession_number":"0001193125-26-226613","importance":30},{"ts":"2026-05-15","kind":"sec.filing","form_type":"4","title":"4 — Karyopharm Therapeutics Inc. — 2026-05-15","url_slug":"/sec/cik-0001503802/4/0001193125-26-226616","accession_number":"0001193125-26-226616","importance":30},{"ts":"2026-05-15","kind":"sec.filing","form_type":"4","title":"4 — Karyopharm Therapeutics Inc. — 2026-05-15","url_slug":"/sec/cik-0001503802/4/0001193125-26-226652","accession_number":"0001193125-26-226652","importance":30},{"ts":"2026-05-15","kind":"sec.filing","form_type":"4","title":"4 — Karyopharm Therapeutics Inc. — 2026-05-15","url_slug":"/sec/cik-0001503802/4/0001193125-26-226685","accession_number":"0001193125-26-226685","importance":30},{"ts":"2026-05-15","kind":"sec.filing","form_type":"4","title":"4 — Karyopharm Therapeutics Inc. — 2026-05-15","url_slug":"/sec/cik-0001503802/4/0001193125-26-226697","accession_number":"0001193125-26-226697","importance":30},{"ts":"2026-05-14","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Karyopharm Therapeutics Inc. — 2026-05-14","url_slug":"/sec/cik-0001503802/10-q/0001193125-26-222827","accession_number":"0001193125-26-222827","importance":45},{"ts":"2026-05-14","kind":"sec.insider.s","reporter":"Paulson Richard A.","title":"President and CEO","shares":2203,"price_per_share":9.5,"usd_value":20929,"security_title":"Common Stock","importance":35.0209285},{"ts":"2026-05-14","kind":"sec.insider.s","reporter":"Rangwala Reshma","title":"EVP & Chief Medical Officer","shares":408,"price_per_share":9.5,"usd_value":3876,"security_title":"Common Stock","importance":35.003876},{"ts":"2026-05-14","kind":"sec.insider.s","reporter":"Poulton Stuart","title":"EVP, Chief Development Officer","shares":403,"price_per_share":9.5,"usd_value":3829,"security_title":"Common Stock","importance":35.0038285},{"ts":"2026-05-14","kind":"sec.insider.s","reporter":"Cheng Sohanya Roshan","title":"EVP & Chief Commercial Officer","shares":324,"price_per_share":9.5,"usd_value":3078,"security_title":"Common Stock","importance":35.003078},{"ts":"2026-05-14","kind":"sec.insider.s","reporter":"Mano Michael","title":"EVP, CLO&Secretary","shares":266,"price_per_share":9.5,"usd_value":2527,"security_title":"Common Stock","importance":35.002527},{"ts":"2026-05-14","kind":"sec.insider.s","reporter":"Abate Kristin","title":"Chief Accounting Officer","shares":53,"price_per_share":9.5,"usd_value":504,"security_title":"Common Stock","importance":35.0005035},{"ts":"2026-05-14","kind":"sec.filing","form_type":"8-K","title":"8-K — Karyopharm Therapeutics Inc. — 2026-05-14","url_slug":"/sec/cik-0001503802/8-k/0001193125-26-222808","accession_number":"0001193125-26-222808","importance":35},{"ts":"2026-05-14","kind":"sec.filing","form_type":"EFFECT","title":"EFFECT — Karyopharm Therapeutics Inc. — 2026-05-14","url_slug":"/sec/cik-0001503802/effect/9999999995-26-001655","accession_number":"9999999995-26-001655","importance":30},{"ts":"2026-05-14","kind":"sec.filing","form_type":"EFFECT","title":"EFFECT — Karyopharm Therapeutics Inc. — 2026-05-14","url_slug":"/sec/cik-0001503802/effect/9999999995-26-001656","accession_number":"9999999995-26-001656","importance":30},{"ts":"2026-05-14","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Karyopharm Therapeutics Inc. — 2026-05-14","url_slug":"/sec/cik-0001503802/schedule-13g-a/0001011438-26-000310","accession_number":"0001011438-26-000310","importance":30},{"ts":"2026-05-13","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Karyopharm Therapeutics Inc. — 2026-05-13","url_slug":"/sec/cik-0001503802/schedule-13g/0000919574-26-002939","accession_number":"0000919574-26-002939","importance":55},{"ts":"2026-05-13","kind":"sec.insider.a","reporter":"Mano Michael","title":"EVP, CLO&Secretary","shares":700,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-13","kind":"sec.insider.a","reporter":"Paulson Richard A.","title":"President and CEO","shares":4920,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-13","kind":"sec.insider.a","reporter":"Cheng Sohanya Roshan","title":"EVP & Chief Commercial Officer","shares":947,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-13","kind":"sec.insider.a","reporter":"Abate Kristin","title":"Chief Accounting Officer","shares":121,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-13","kind":"sec.insider.a","reporter":"Poulton Stuart","title":"EVP, Chief Development Officer","shares":896,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-13","kind":"sec.insider.a","reporter":"Rangwala Reshma","title":"EVP & Chief Medical Officer","shares":947,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-12","kind":"sec.filing","form_type":"CORRESP","title":"CORRESP — Karyopharm Therapeutics Inc. — 2026-05-12","url_slug":"/sec/cik-0001503802/corresp/0001193125-26-219339","accession_number":"0001193125-26-219339","importance":30},{"ts":"2026-05-12","kind":"sec.filing","form_type":"CORRESP","title":"CORRESP — Karyopharm Therapeutics Inc. — 2026-05-12","url_slug":"/sec/cik-0001503802/corresp/0001193125-26-219351","accession_number":"0001193125-26-219351","importance":30},{"ts":"2026-05-11","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Karyopharm Therapeutics Inc. — 2026-05-11","url_slug":"/sec/cik-0001503802/schedule-13g-a/0001493152-26-022238","accession_number":"0001493152-26-022238","importance":30},{"ts":"2026-05-07","kind":"sec.filing","form_type":"UPLOAD","title":"UPLOAD — Karyopharm Therapeutics Inc. — 2026-05-07","url_slug":"/sec/cik-0001503802/upload/0000000000-26-004694","accession_number":"0000000000-26-004694","importance":30},{"ts":"2026-05-07","kind":"sec.filing","form_type":"UPLOAD","title":"UPLOAD — Karyopharm Therapeutics Inc. — 2026-05-07","url_slug":"/sec/cik-0001503802/upload/0000000000-26-004695","accession_number":"0000000000-26-004695","importance":30}]}